ArticleFrontiers in pharmacology2020

Hematological Malignancy Specific Patient-Reported Outcome Measure (HM-PRO): Construct Validity Study.

Pushpendra Goswami et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.